EU/3/18/1977

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1977) was granted by the European Commission to GW Research Ltd, United Kingdom, for cannabidivarin for the treatment of fragile X syndrome.

Key facts

Active substance
Cannabidivarin
Disease / condition
Treatment of fragile X syndrome
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1977

Sponsor's contact details

GW Research Ltd
Sovereign House
Vision Park
Chivers Way, Histon
Cambridge CB24 9BZ
United Kingdom
Tel. +44 (0)1223 266 800
E-mail: medicalinformation@gwpharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating